| 熊 伟,费润欢,周克湘,张 迁,李小燕.双歧杆菌乳杆菌三联活菌片联合血必净注射液对急性胰腺炎患者炎性介质、细胞免疫指标及肠黏膜屏障功能的影响[J].现代生物医学进展英文版,2020,(18):3498-3501. |
| 双歧杆菌乳杆菌三联活菌片联合血必净注射液对急性胰腺炎患者炎性介质、细胞免疫指标及肠黏膜屏障功能的影响 |
| Effects of Bifidobacterium Lactobacillus Triple Viable Tablet Combined with Xuebijing Injection on Inflammatory Mediators, Cellular Immune Indexes and Intestinal Mucosal Barrier Function in Patients with Severe Acute Pancreatitis |
| Received:December 28, 2019 Revised:January 24, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.18.022 |
| 中文关键词: 双歧杆菌乳杆菌三联活菌片 血必净注射液 急性胰腺炎 炎性介质 细胞免疫 肠黏膜屏障功能 |
| 英文关键词: Bifidobacterium Lactobacillus triple viable tablet Xuebijing injection Severe acute pancreatitis Inflammatory mediators Cellular immunity Intestinal mucosal barrier function |
| 基金项目:重庆市教委科学技术研究项目（KJQN201701303） |
| Author Name | Affiliation | E-mail | | XIONG Wei | Department of Gastroenterology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China | 153536698@qq.com | | FEI Run-huan | Institute of Digestive Diseases of Whole Army, Southwest Hospital of Army Medical University, Chongqing, 400038, China | | | ZHOU Ke-xiang | Department of Gastroenterology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China | | | ZHANG Qian | Department of Gastroenterology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China | | | LI Xiao-yan | Department of Gastroenterology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China | |
|
| Hits: 830 |
| Download times: 533 |
| 中文摘要: |
| 摘要 目的：探讨血必净注射液联合双歧杆菌乳杆菌三联活菌片治疗急性胰腺炎（SAP）患者的临床疗效。方法：选取2016年9月~2019年4月期间我院收治的SAP患者119例，根据随机数字表法将患者随机分为对照组（n=59）和研究组（n=60），对照组给予血必净注射液治疗，研究组在对照组的基础上联合双歧杆菌乳杆菌三联活菌片治疗，比较两组临床疗效，炎性介质、细胞免疫指标水平、肠黏膜屏障功能及不良反应发生情况。结果：研究组治疗7d后总有效率高于对照组（P<0.05）。两组治疗期间未见药品不良反应发生。两组血清内毒素、二胺氧化酶（DAO）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）以及C反应蛋白（CRP）、CD8+水平均降低，且研究组低于对照组（P<0.05），CD4+/ CD8+ 、CD4+、NK细胞水平升高，且研究组高于对照组（P<0.05）。结论：SAP患者在血必净的基础上联合双歧杆菌乳杆菌三联活菌片治疗，可提高机体细胞免疫功能，改善炎性因子水平和肠黏膜屏障功能，且用药安全性较好，临床应用价值较高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of Xuebijing injection combined with Bifidobacterium Lactobacillus triple viable tablet in the treatment of acute pancreatitis (SAP). Methods: 119 patients with SAP who were admitted to our hospital from September 2016 to April 2019 were selected, they were randomly divided into control group (n=59) and study group (n=60) according to the method of random number table. The control group was treated with Xuebijing injection. The study group was treated with Bifidobacterium Lactobacillus triple viable tablet on the basis of the control group. The clinical efficacy, inflammatory mediators, cellular immune indexes, intestinal mucosal barrier function and adverse reactions were compared between the two groups. Results: The total effective rate of the study group was higher than that of the control group after 7 days treatment (P<0.05). The levels of serum endotoxin, diamine oxidase (DAO), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), CD8+ in the two groups were decreased, and those of the study group were lower than those of the control group (P<0.05). The levels of CD4+/CD8+, CD4+, NK cells were increased, and those of the study group were lower than those of the control group (P<0.05). There was no adverse drug reaction in the two groups. Conclusion: Bifidobacterium lactobacillus triple viable tablet combined with Xuebijing injection on SAP can improve the immune function, the level of inflammatory factors and the intestinal mucosal barrier function, which has good drug safety, and the clinical application value is high. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
